This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

John Northover, MA, FRCS; Joan Houghton; Tina Lennon
for the CRC/NIH CEA Trial Working Party CRC Clinical Trials Centre London, England

JAMA. 1994;272(1):31.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—We have been following with interest the correspondence in response to the recently published article by Dr Moertel and associates¹ on carcinoembryonic antigen (CEA) monitoring in the postoperative follow-up of patients treated for colorectal cancer. Moertel et al conclude that not only is such monitoring poorly carried out, but that it has little value in the early detection of resectable recurrence. Furthermore, the financial resources could be more appropriately diverted to research. We too have been concerned with the controversy surrounding the role of CEA monitoring in such patients, but felt that without a clear and reliable demonstration of efficacy, the only solution was to organize a prospective, randomized, controlled, double-blinded trial. In 1982, we launched the CRC/NIH CEA Second-Look Trial, which was designed to give a definitive evaluation of CEA. Patients were recruited from the United Kingdom and Europe, and by February 1993, 1447 patients . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?